Activation of the nuclear factor, erythroid 2-like 2 (Nrf2), a major transcription factor of the antioxidant defense system, is an emerging therapeutic strategy in Sickle Cell Disease (SCD). Here, NFE2L2 is linked to sickle cell disease.